甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的效果及对外周血肿瘤异常蛋白、血管内皮生长因子与基质金属蛋白酶-9的影响

Effect of apatinib mesylate combined with docetaxel in the second-line treatment of advanced gastric cancer and its influences on peripheral blood tumor abnormal protein,vascular endothelial growth factor and matrix metalloproteinase-9

目的探讨甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的效果及对外周血肿瘤异常蛋白、血管内皮生长因子(VEGF)与基质金属蛋白酶-9(MMP-9)的影响。方法选取2020年3月至2022年3月收治的90例晚期胃癌患者为研究对象,随机将其分为对照组与观察组,各45例。对照组采用多西他赛化疗方案,观察组在对照组基础上加甲磺酸阿帕替尼治疗。比较两组的治疗效果。结果观察组的疾病控制率高于对照组(P<0.05)。治疗后,观察组的糖类抗原19-9(CA19-9)、肿瘤特异性生长因子(TSGF)及癌胚抗原(CEA)水平均低于对照组(P<0.05)。治疗后,观察组的VEGF、MMP-9、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平均低于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的效果较好,可对外周血肿瘤异常蛋白有良好的抑制作用,同时还能调节VEGF、MMP-9水平,且不会增加不良反应发生风险,值得应用与推广。

Objective To investigate the effect of apatinib mesylate combined with docetaxel in the second-line treatment of advanced gastric cancer and its influences on peripheral blood tumor abnormal protein,vascular endothelial growth factor(VEGF)and matrix metalloproteinase-9(MMP-9).Methods A total of 90 patients with advanced gastric cancer admitted from March 2020 to March 2022 were selected as the study subjects,and the patients were randomly divided into control group and observation group,with 45 cases in each group.The control group was treated with docetaxel chemotherapy regimen,and the observation group was treated with apatinib mesylate on the basis of the control group.The therapeutic effects of the two groups were compared.Results The disease control rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of carbohydrate antigen 19-9(CA19-9),tumor supplied group of factors(TSGF)and carcinoembryonic antigen(CEA)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of VEGF,MMP-9,tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Apatinib mesylate combined with docetaxel in the second-line treatment of advanced gastric cancer has better effect,it can inhibit the peripheral blood tumor abnormal protein,and regulate the levels of VEGF and MMP-9,and does not increase the risk of adverse reactions,which is worthy of application and promotion.